Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas

NCT02243605 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02243605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02243605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 19, 2014
Completion date
July 23, 2027
Enrollment
90 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic ewing sarcoma, metastatic osteosarcoma, recurrent ewing sarcoma, recurrent osteosarcoma, stage iii osteosarcoma ajcc v7, stage iv osteosarcoma ajcc v7, stage iva osteosarcoma ajcc v7, stage ivb osteosarcoma ajcc v7, unresectable ewing sarcoma, unresectable osteosarcoma